Table 1 Characteristics of the trial population at baseline (n = 16)
Characteristics | Median (IQR) | |
|---|---|---|
Age (years) | 57 (55–68) | |
Mean (IQR) | ||
BMI | 22.1 (19.7–24.5) | |
No. (%) | ||
Type of cancer | ||
Ovary | 12 (75%) | |
Uterus corpus | 4 (25%) | |
Histology | Ovary | Uterus corpus |
Serous carcinoma | 1 (6.3%) | 0 (0%) |
Endometrioid carcinoma | 4 (25%) | 3 (18.8%) |
Clear cell carcinoma | 6 (37.5%) | 0 (0%) |
Carcinosarcoma | 0 (0%) | 1 (6.3%) |
Mixed carcinoma | 1 (6.3%) | 0 (0%) |
Stage of cancer | Ovary | Uterus corpus |
I | 7 (43.8%) | 1 (6.3%) |
II | 1 (6.3%) | 0 (0%) |
III | 4 (25%) | 2 (12.5%) |
IV | 0 (0%) | 1 (6.3%) |
Location of VTE | ||
DVT | 12 (75%) | |
PE + DVT | 4 (25%) | |
Edoxaban administration | ||
60 mg | 3 (19%) | |
30 mg | 13 (81%) | |
History of previous thrombosis or thrombotic predisposition-no | 0 | |